Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Dentsply Sirona Inc.

XRAY

FAVORABLE

June 1, 2026

Research Conclusion

At ~$19 (May 2026), Dentsply Sirona is a deep-value dental turnaround with 83% probability-weighted upside to $35 and 4.4:1 bull/bear asymmetry. Fair value $28-$42 (mid $35). Thesis rests on (a) Simon Campion turnaround execution since Sept 2023 showing in margin recovery, (b) $100M+ restructuring savings flowing to FY25-26 EBITDA, (c) 3-year deleveraging $2.4B → $1.8B, (d) multiple re-rating from 7-8x toward peer 10-12x. Recommended stance: Speculative Buy for deep-value sleeves only. 18% bear case (-37%) reflects material execution risk: sustained CTS equipment weakness or SEC overhang could prolong multiple compression.

Company Overview & Moat Assessment

Dentsply Sirona (NASDAQ: XRAY) is a global dental products manufacturer (merged 2016). HQ Charlotte, NC. Two segments: Essential Dental Solutions (EDS)—consumables, endodontics, orthodontics (~52% revenue)—and Connected Technology Solutions (CTS)—equipment (CEREC CAD/CAM, imaging, SureSmile aligners) (~48%). FY2024 revenue ~$3.77B; adj EBITDA margin 20%; adj EPS ~$1.95. Struggles: post-merger integration, SEC investigation (resolved), CTS equipment cycle pressure, China VBP. CEO Simon Campion (ex-BD, Sept 2023) driving turnaround. Net debt $2.4B (3.2x EBITDA; target <2.5x). 205M diluted shares; $0.40/yr dividend.

▲ Bull Case

  • ◆CTS equipment recovery: Cycle bottomed; SureSmile + CEREC growth + China stabilization deliver +5% CTS growth FY26+.
  • ◆Margin reaches 25% by FY27 as restructuring savings and revenue leverage compound; EPS $3+ achievable.
  • ◆Multiple expands to 13x EV/EBITDA as investment-grade credit restored and governance resolved; implies price $50.

▼ Bear Case

  • ◆CTS equipment weakness persists: China VBP expansion and Europe softness sustain -3% CTS declines.
  • ◆Margin stalls at 20%: Cost saves offset by volume deleverage; restructuring momentum lost.
  • ◆Multiple remains 7-8x: Defensive valuation trap; no catalyst materializes for re-rating to peer levels.
Primary Debate on Wall Street

“The core debate: 'Is Campion's turnaround real or a story?' Bull frame: cost program + EDS stability + CTS bottoming = path to $35+. Bear frame: secular dental headwinds + China + competition = trapped at $15-20. Sell-side mixed: ~5 Buy / 8 Hold / 3 Sell. Consensus PT range $20-$40, reflecting divergence on execution credibility.”

Top Catalysts
  • ◆Q4 2024 / FY2024 earnings — first potential positive organic growth comp
  • ◆Q1-Q2 2025 organic growth confirmation — CTS inflection signal
  • ◆Margin trajectory — $100M+ restructuring savings flowing through to EBITDA
  • ◆FY2025 guidance raise — credibility restoration for turnaround thesis
  • ◆SEC settlement clarity — overhang removal and governance improvement
  • ◆China revenue stabilization — VBP impact containment
  • ◆Investor Day strategic update — roadmap to $35+ fair value
Top Risks
  • ◆CTS equipment weakness extends — primary thesis kill switch
  • ◆China VBP expansion accelerates — direct revenue headwind
  • ◆SEC investigation overhang persists — execution distraction
  • ◆Goodwill impairment write-down — turnaround failure signal
  • ◆Credit rating downgrade — refinancing risk and rising interest expense
  • ◆Multiple stays below 6x despite EBITDA recovery — structural market skepticism
  • ◆Campion departure — execution risk crystallizes

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/XRAY/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.